During the recent session, Takeda Pharmaceutical Co ADR (NYSE:TAK)’s traded shares were 2.26 million, with the beta value of the company hitting 0.57. At the last check today, the stock’s price was $14.26, reflecting an intraday loss of -0.35% or -$0.05. The 52-week high for the TAK share is $15.39, that puts it down -7.92 from that peak though still a striking 11.85% gain since the share price plummeted to a 52-week low of $12.57. The company’s market capitalization is $45.20B, and the average intraday trading volume over the past 10 days was 1.75 million shares, and the average trade volume was 2.26 million shares over the past three months.
Takeda Pharmaceutical Co ADR (TAK) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.06. TAK has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Takeda Pharmaceutical Co ADR (NYSE:TAK) trade information
Takeda Pharmaceutical Co ADR (TAK) registered a -0.35% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -0.35% in intraday trading to $14.26, hitting a weekly high. The stock’s 5-day price performance is -1.18%, and it has moved by -3.78% in 30 days. Based on these gigs, the overall price performance for the year is -6.92%. The short interest in Takeda Pharmaceutical Co ADR (NYSE:TAK) is 8.42 million shares and it means that shorts have 4.7 day(s) to cover.
Takeda Pharmaceutical Co ADR (TAK) estimates and forecasts
Statistics show that Takeda Pharmaceutical Co ADR has underperformed its competitors in share price, compared to the industry in which it operates. Takeda Pharmaceutical Co ADR (TAK) shares have gone up 6.66% during the last six months, with a year-to-date growth rate less than the industry average at -7.78% against 19.50.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -12.87%. While earnings are projected to return -21.80% in 2024, the next five years will return 20.67% per annum.
TAK Dividends
Takeda Pharmaceutical Co ADR is due to release its next quarterly earnings on 2024-Oct-31. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance. Investors should also take the other fundamental and operational aspects into account before investing in the stock. The forward dividend ratio for Takeda Pharmaceutical Co ADR is 0.29, with the dividend yield indicating at 2.05 percent, continuing the trend of increasing dividends in recent years. The average dividend yield of the company for the last 5 years is 4.7%.
Takeda Pharmaceutical Co ADR (NYSE:TAK)’s Major holders
Takeda Pharmaceutical Co ADR insiders own 0.01% of total outstanding shares while institutional holders control 2.31%, with the float percentage being 2.31%. CAPITAL RESEARCH GLOBAL INVESTORS is the largest shareholder of the company, while 342.0 institutions own stock in it. As of 2024-06-30, the company held over 13.13 million shares (or 0.8366% of all shares), a total value of $169.86 million in shares.
The next largest institutional holding, with 7.74 million shares, is of MONDRIAN INVESTMENT PARTNERS LTD’s that is approximately 0.4932% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $108.34 million.
